Revenue and net profit grew year-over-year for the quarter and half-year ended September 30, 2025, with strong operating cash flows and no audit qualifications. The company remains focused on its pharmaceuticals segment and maintains a robust financial position.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.